LONGTERM TREATMENT EFFECTS OF INOTERSEN ON QUALITY OF LIFE IN PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS WITH POLYNEUROPATHY

被引：0
|
作者：
Brown, Duncan
Karam, Chafic
Yang, Min
Done, Nicolae
Zhu, JingJing
Greatsinger, Ali
Bozas, Ana
Llonch, Montserrat Vera
Signorovitch, James
机构：
来源：
MUSCLE & NERVE | 2021年 / 64卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
105
引用
收藏
页码：S57 / S57
页数：1
相关论文
共 50 条
  • [21] The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
    Aaron Yarlas
    Andrew Lovley
    Duncan Brown
    Montserrat Vera-Llonch
    Sami Khella
    Chafic Karam
    BMC Neurology, 23
  • [22] EFFICACY OF INOTERSEN FOR NEUROPATHIC IMPAIRMENT SCORES IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS WITH POLYNEUROPATHY
    Yarlas, Aaron
    Lovley, Andrew
    Brown, Duncan
    Llonch, Montserrat Vera
    Karam, Chafic
    Khella, Sami
    MUSCLE & NERVE, 2021, 64 : S61 - S61
  • [23] The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
    Yarlas, Aaron
    Lovley, Andrew
    Brown, Duncan
    Vera-Llonch, Montserrat
    Khella, Sami
    Karam, Chafic
    BMC NEUROLOGY, 2023, 23 (01)
  • [24] Evaluation of methodologies for indirect comparison of eplontersen and vutrisiran for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Karam, Chafic
    Gillmore, Julian
    Chen, Gengshi
    Jenkins, Nia
    Hale, Mike
    Taylor, Gemma
    Chen, Jersey
    Viney, Nicholas
    Schneider, Eugene
    NEUROLOGY, 2023, 100 (17)
  • [25] A mini-review of Vutrisiran and Eplontersen in hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Olatunji, Gbolahan
    Kokori, Emmanuel
    Abraham, Israel Charles
    Omoworare, Oluwatobi
    Olatunji, Doyin
    Ezeano, Chimezirim
    Emmanuel Adeoba, Babawale
    Stanley, Anthony Chidera
    Oluwatobiloba, Awoyinfa Michael
    Oluwademilade, Omidiran Basit
    Shimelis, Kale Mekoya
    Olanisa, Olawale
    Aderinto, Nicholas
    MEDICINE, 2024, 103 (26) : e38767
  • [26] Effectiveness of patisiran after switching from tafamidis for the treatment of hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Labeyrie, Celine
    Merkel, Madeline
    Sethi, Sakshi
    Popadic, Lyuba
    Yang, Hongbo
    Sweetser, Marianne T.
    Lin, Hollis
    Adams, David
    EUROPEAN JOURNAL OF NEUROLOGY, 2024, 31 (09)
  • [27] Inotersen to Treat Polyneuropathy Associated with Hereditary Transthyretin (hATTR) Amyloidosis
    Robinson, Christopher
    Pham, Cynthia
    Zamarripa, Alec M.
    Dugay, Chase S.
    Lee, Christopher A.
    Berger, Amnon A.
    Landman, Avi
    Cornett, Elyse M.
    Kassem, Hisham
    Kaye, Alan D.
    Urits, Ivan
    Viswanath, Omar
    Ganti, Latha
    HEALTH PSYCHOLOGY RESEARCH, 2022, 10 (05):
  • [28] Identifying Mixed Phenotype: Evaluating the Presence of Polyneuropathy in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Cardiomyopathy
    Grogan, Martha
    Hawkins, Philip N.
    Kristen, Arnt V.
    Berk, John L.
    Suhr, Ole B.
    Lin, Hollis
    Merkel, Madeline
    McManus, Anastasia
    Powell, Christine
    Vest, John
    Karsten, Verena
    Judge, Daniel P.
    JOURNAL OF CARDIAC FAILURE, 2019, 25 (08) : S9 - S10
  • [29] Impact of vutrisiran on exploratory cardiac parameters in hereditary transthyretin-mediated amyloidosis with polyneuropathy
    Garcia-Pavia, Pablo
    Grogan, Martha
    Kale, Parag
    Berk, John L.
    Maurer, Mathew S.
    Conceicao, Isabel
    Di Carli, Marcelo
    Solomon, Scott D.
    Chen, Chongshu
    Yureneva, Elena
    Vest, John
    Gillmore, Julian D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2024, 26 (02) : 397 - 410
  • [30] Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis
    Dixon, Stacy
    Kang, Xuan
    Quan, Dianna
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2023, 19 : 973 - 981
12345